Patent · US Active

Reconstituted high density lipoprotein formulation and production method thereof

US11723953B2 · kind B2 · utility

0Cited by

11References

12Claims

0Family size

Assignee

CSL LIMITED · AU

Inventors

Samuel Wright · New York, US
Martin Imboden · Münsingen, CH
Reinhard Bolli · Worb, CH
Marcel Waelchli · Rüti, CH

Key dates

Filing date	Jul 6, 2021
Grant date	Aug 15, 2023
Priority date	—
Expiry date	Jul 6, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.